Addiction Medicine
Conference Coverage
Higher buprenorphine doses help OUD patients stay in treatment
Opioid users stick around when they get more withdrawal relief, addiction clinic finds.
Conference Coverage
Buprenorphine update: Looser rules and a helpful injectable
As overdose epidemic continues, new regulations change landscape for opioid addiction therapy.
Latest News
Exercise and empathy can help back pain patients in primary care
Recent research suggests limited pain relief from analgesics and antidepressants, but patients report that doctors’ behavior makes a difference in...
Practice Alert
Talking tobacco with youth? Ask the right questions
Children and adolescents in the United States are smoking cigarettes less—but use of “vapes” is taking their place. Effective prevention starts...
News from the FDA/CDC
FDA approves buprenorphine injection for opioid use disorder
Brixadi is approved in both weekly and monthly subcutaneous injectable formulations at varying doses.
News from the FDA/CDC
Overdose deaths mark another record year, but experts hopeful
“But these numbers are still extraordinarily high. We shouldn’t suggest the crisis is in any way over.”
Commentary
Balancing needs and risks as the opioid pendulum swings
The CDC encourages clinicians to find a balance of the potential benefits and harms and to avoid inflexibility.
News from the FDA/CDC
FDA moves to curb misuse of ADHD meds
The boxed warning will also advise heath care professionals to monitor patients closely for signs and symptoms of misuse, abuse, and addiction.
Applied Evidence
Medication-assisted recovery for opioid use disorder: A guide
Considering offering medical intervention for OUD to reduce mortality? It’s essential to understand the clinical benefits, limitations, and...
Guidance for Practicing Primary Care
Thoughts on the CDC update on opioid prescribing guidelines
While the guidelines do a great job recommending how to prescribe opioids, they do not go into any depth discussing other treatment options.
From the Journals
Young men at highest schizophrenia risk from cannabis abuse
For young men aged 21-30, the proportion of preventable schizophrenia cases related to cannabis abuse disorder may be as high as 30%.